The Cancer Letter

Inside information on cancer research and drug development

In Brief

Gerrit Los named vice president of pharmacology at AnaptysBio Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

GERRIT LOS was named vice president of pharmacology at AnaptysBio Inc.

Los will lead translational biology across the company’s antibody pipeline, including programs focused in immuno-oncology. Los will report to Macro Londei, AnaptysBio’s chief development officer.

Los joins AnaptysBio from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics. Prior to Five Prime, Los was head of cancer biology at Pfizer, where he directed teams responsible for the development of several targeted cancer therapeutics, including crizotinib, axitinib and palbociclib.

Prior to Pfizer, Los was an adjunct professor at the University of California San Diego where his work focused on identifying response markers in cancer.

Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: We must support our junior colleagues
“Empathy and listening is a key place to start”

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
By W. Kimryn Rathmell
Guest Editorial

Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunity
Weill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration

The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 
By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account